• Home
  • Daniel Pleguezuelo
Daniel Pleguezuelo

Daniel Pleguezuelo
Hospital Universitario 12 de Octubre | Clínica Dr. Pleguezuelo

MD

About

25
Publications
2,175
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
332
Citations

Publications

Publications (25)
Article
Full-text available
  • [...]
Common variable immunodeficiency (CVID) is characterized by hypogammaglobulinemia and/or a defective antibody response to T-dependent and T-independent antigens. CVID response to immunization depends on the antigen type, the vaccine mechanism, and the specific patient immune defect. In CVID patients, humoral and cellular responses to the currently...
Article
  • [...]
Background: The aim of the study was to analyze the clinical manifestations and outcome of the oldest old (people aged ≥85 years) who were admitted to the hospital with a confirmed influenza A virus infection in comparison with younger patients and to assess the role of inflammation in the outcome of influenza infection in this population. Method...
Article
Full-text available
  • [...]
Autosomal inborn errors of type I IFN immunity and autoantibodies against these cytokines underlie at least 10% of critical COVID-19 pneumonia cases. We report very rare, biochemically deleterious X-linked TLR7 variants in 16 unrelated male individuals aged 7 to 71 years (mean: 36.7 years) from a cohort of 1,202 male patients aged 0.5 to 99 years (...
Article
Full-text available
  • [...]
Autosomal inborn errors of type I IFN immunity and autoantibodies against these cytokines underlie at least 10% of critical COVID-19 pneumonia cases. We report very rare, biochemically deleterious X-linked TLR7 variants in 16 unrelated male individuals aged 7 to 71 years (mean: 36.7 years) from a cohort of 1,202 male patients aged 0.5 to 99 years (...
Article
Full-text available
  • [...]
Primary immune regulatory disorders (PIRD) are associated with autoimmunity, autoinflammation and/or dysregulation of lymphocyte homeostasis. Autoimmune lymphoproliferative syndrome (ALPS) is a PIRD due to an apoptotic defect in Fas-FasL pathway and characterized by benign and chronic lymphoproliferation, autoimmunity and increased risk of lymphoma...
Article
Full-text available
  • [...]
Recurrent pregnancy loss (RPL) affects up to 6% of couples. Although chromosomal aberrations of the embryos are considered the leading cause, 50% of cases remain unexplained. Antiphospholipid Syndrome is a known cause in a few cases. Antiphospholipid antibodies (aPL) anticardiolipin, anti-Beta-2-Glycoprotein-I and Lupus Anticoagulant (criteria aPL)...
Article
Full-text available
  • [...]
Introduction Monoclonal antibodies (mAb) targeting plasma cells are malignant gammopathy designed and approved therapies. In recent years, these antibodies have also been increasingly introduced for non-malignant conditions such as autoimmune-mediated diseases. The Anti-Phospholipid Syndrome (APS) is an immune-mediated disorder in which autoantibod...
Article
Full-text available
  • [...]
Objective: Patients with coronavirus disease 2019 (COVID-19) present coagulation abnormalities and thromboembolic events that resemble antiphospholipid syndrome (APS). This work has aimed to study the prevalence of APS-related antigens, antibodies, and immune complexes in patients with COVID-19 and their association with clinical events. Methods:...
Article
Full-text available
  • [...]
The immune response type organized against viral infection is determinant in the prognosis of some infections. This work has aimed to study Th polarization in acute COVID-19 and its possible association with the outcome through an observational prospective study. Fifty-eight COVID-19 patients were recruited in the Medicine Department of the hospita...
Article
Full-text available
  • [...]
The specific value of IgA Anti-β2glycoprotein I antibodies (aB2GP1) in the diagnosis and management of antiphospholipid syndrome (APS) is still controversial and a matter of active debate. The relevance of the IgA aB2GP1 isotype in the pathophysiology of APS has been increasingly studied in the last years. There is well know that subjects with mult...
Article
Full-text available
  • [...]
Objective To compare characteristics, pregnancies and treatments during pregnancies of seronegative and seropositive antiphospholipid syndrome (APS), to analyse factors associated with obstetrical outcome. Patients and methods Inclusion criteria were: (1) thrombotic and/or obstetrical APS (Sydney criteria); (2) absence of conventional antiphosphol...
Article
Full-text available
  • [...]
Objectives To compare clinical characteristics, pregnancies, and treatments during pregnancies of seronegative and seropositive APS, and analyse factors associated with adverse obstetrical outcomes. Methods Inclusion criteria were: (1) thrombotic arterial and/or venous; and /or obstetrical primary clinical APS (Sydney criteria); (2) absence of con...
Article
Full-text available
  • [...]
In transplanted intestines, depletion of T cells together with long term persistence of ILC are observed, suggesting ILC insensitivity to immunosuppressive drugs. To further analyze helper ILC (hILC) apparent resistance to therapy, cytotoxic ILC (NK cells), hILC subsets (ILC1, ILC2 and ILC precursors (ILCP)), and their signature cytokines (IFNγ, IL...
Article
Full-text available
  • [...]
Background: The presence of anti-Beta 2 glycoprotein antibodies (aB2GP1) of IgA isotype is common in patients with functional impairment of the organs in which B2GP1 is elaborated. Pretransplant IgA aB2GP1 has been associated with increased risk of thrombosis in kidney and heart transplanted patients and has also been related with early mortality a...
Article
  • [...]
Background An important complication of kidney transplant is the graft loss, mainly by thrombosis, in the first weeks after transplantation. Early graft loss afect to 5-8% of the patients and this percentage has remained unchanged in recent decades. Prevalence of a antiphospholipid antibody: anti b2-glycoprotein-I (B2GP1) of IgA isotype in p...
Article
Full-text available
  • [...]
Background and objectives: Mortality of patients on hemodialysis (HD) remains very high despite recent improvements in HD techniques. Cardiovascular (CV) complications and infections are the main causes of death. Some studies suggest that disturbances in the immune system could play a role in this disproportionate mortality, through the links of i...
Article
Full-text available
  • [...]
Background: The antiphospholipid syndrome (APS) is defined by simultaneous presence of vascular clinical events and antiphospholipid antibodies (aPL). The aPL considered as diagnostics are lupus anticoagulant and antibodies anticardiolipin (aCL) and anti-ß2 glycoprotein-I (aB2GP1). During recent years, IgA aB2GP1 antibodies have been associated wi...
Article
  • [...]
BACKGROUND: Early detection of antinuclear antibodies (ANA) in asymptomatic subjects is useful to predict autoimmune diseases years before diagnosis. ANA have been determined by indirect immunofluorescence (IIF) using human epithelial type 2 (HEp-2) cells, which is considered the gold standard technique. Multiplex technology (BioPlex ANA Screen) ha...
Article
  • [...]
Background: Antiphospholipid syndrome is characterized by recurrent thrombosis and gestational morbidity in patients with antiphospholipid autoantibodies (aPLs). Predictive value of the presence of aPLs is low, and new markers are necessary to identify aPL carriers at higher risk and take preventive measures on them. The presence of circulating im...
Article
Selective IgA deficiency (SIgAD) is the most prevalent immunodeficiency worldwide, progressing to common variable immunodeficiency only in few reported cases. We report the case of a Spanish female aged 22 and diagnosed of selective IgA deficiency, a long history of bronchitis, several episodes of pneumonia, bilateral bronchiectasis, normal IgG, Ig...

Network

Cited By

Projects

Projects (3)
Project
1. Find out the prevalence of antiphospholipid antibodies (aPL) excluded of Sidney consensus (expanded aPL: E-aPL) in general population. 2 . Determine presence of E-aPL in patients with clinical manifestations of primary antiphospholipid syndrome (APS) that are negative for other aPL. 3. Determine whether asymptomatic individuals who are positive for IgA aB2GPI develop vascular disease within 5 years of their diagnosis. 4 Identify new biomarkers associated with presence of E-aPL to better identify risk population at and the likelihood of vascular events.
Project
To further explore non-invasive immunological biomarkers, novel strategies to improve cell transplant efficiency,
Project
1. Find out the prevalence of antiphospholipid antibodies (aPL) excluded of Sidney consensus (expanded aPL: E-aPL) in general population. 2 . Determine presence of E-aPL in patients with clinical manifestations of primary antiphospholipid syndrome (APS) that are negative for other aPL. 3. Determine whether asymptomatic individuals who are positive for IgA aB2GPI develop vascular disease within 5 years of their diagnosis. 4 Identify new biomarkers associated with presence of E-aPL to better identify risk population at and the likelihood of vascular events.